Surmodics, Inc. (SRDX)
- Previous Close
34.08 - Open
34.38 - Bid 34.56 x 100
- Ask 34.91 x 100
- Day's Range
34.18 - 34.78 - 52 Week Range
16.79 - 39.41 - Volume
35,785 - Avg. Volume
73,284 - Market Cap (intraday)
493.681M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
36.06 - EPS (TTM)
0.96 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
58.25
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
www.surmodics.comRecent News: SRDX
Performance Overview: SRDX
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SRDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SRDX
Valuation Measures
Market Cap
493.68M
Enterprise Value
486.40M
Trailing P/E
36.06
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.41
Price/Book (mrq)
3.98
Enterprise Value/Revenue
3.40
Enterprise Value/EBITDA
16.44
Financial Highlights
Profitability and Income Statement
Profit Margin
9.44%
Return on Assets (ttm)
6.61%
Return on Equity (ttm)
11.92%
Revenue (ttm)
142.96M
Net Income Avi to Common (ttm)
13.5M
Diluted EPS (ttm)
0.96
Balance Sheet and Cash Flow
Total Cash (mrq)
40.94M
Total Debt/Equity (mrq)
27.16%
Levered Free Cash Flow (ttm)
21.97M
Research Analysis: SRDX
Company Insights: SRDX
SRDX does not have Company Insights